Spravato was previously approved by the FDA in 2019 for treatment-resistant depression, but it was required to be used with an oral antidepressant. The new FDA approval means people can use the ...

The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression, J&J said in a news release on Tuesday, Jan. 21. The decision came after a ...

SPRAVATO® alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, with numerical improvements across all 10 MADRS items ...

Discover six of the top psychedelic companies developing novel drugs to expand the treatment scope for mental health ...

Jan. 21 (UPI) -- The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial (ClinicalTrials.gov Identifier ...

Treating Depression with Spravato at Viking Psychiatry by: Adam Solarczyk, Jessica Williams Posted: Jun 18, 2024 / 01:05 PM EDT Updated: Jun 18, 2024 / 06:52 PM EDT ...

Spravato is classified as a Schedule III controlled substance. Due to the risk of sedation, dissociation, and respiratory depression, it must be administered under the direct supervision of a ...

SPRAVATO ® alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, with numerical improvements across all 10 MADRS items ...

Depression is serious, and can even be life-threatening. While Spravato isn’t perfect and does have risks, it offers new hope for people who haven’t found relief with other treatments.